# Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

> **NCT05328102** · PHASE2 · TERMINATED · sponsor: **Xencor, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Diffuse Large-cell B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Plamotamab
- **BIOLOGICAL:** Tafasitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05328102
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-15
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-02-21
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study has been terminated early by the sponsor due to business decision.
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328102, "Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05328102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*